Description: Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.
Home Page: www.kadimastem.com
Pinchas Sapir 7
Ness Ziona,
74140
Israel
Phone:
972 73 797 1600
Officers
| Name | Title |
|---|---|
| Mr. Asaf Shiloni | Chief Exec. Officer |
| Dr. Arik Hasson Ph.D. | Exec. VP of Bus. Devel. |
| Dr. Michal Harel Izrael | VP of R&D for ALS and Neurodegenerative Diseases |
| Prof. Michel Revel M.D., Ph.D. | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director |
| Mr. Yossi Ben-Yossef | Honorary Pres & Strategic Consultant |
Exchange: TA
Country: IL
Currency: Israeli Agora (ILA)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.8968 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |